Discussion about this post

User's avatar
Dan's avatar

One thing to always keep front of mind when looking at medical innovation in countries with public health systems and price controls: whether or not the medical companies in those markets are selling into the US markets. I don't know the specifics about Japanese and Korean medical companies, but many European drug and medical device companies are essentially recouping all their fixed costs by selling into the US market, allowing them to sell at prices only slightly above their marginal cost in their home markets. US consumers wind up subsidizing much of the R&D for the entire world as a result, and if we imposed price controls on our markets, it would likely have catastrophic impacts for innovation in countries around the globe.

This is not necessarily an argument that US consumers _should_ keep subsidizing the rest of the world, mind you. But people have gotten so used to free-riding on the US medical system that I tend to think that they'd let innovation collapse before other countries would start picking up their share of the tab. As always, it's a lot easier to see money leaving your bank account right now than foresee the things that will never be developed because they could never be made profitable.

Expand full comment
Matthew's avatar

On #6, your first instincts are right.

There are two ways this paper is wrong.

1) The authors are ignoring a big facet of the world spending on health, the fact that the US has 4.23% of the world's population but accounts for about half of global health spending. The US shouldn't be doing this. We are a big market. Drug companies and Medical Device companies still launch products in the UK and Japan and Germany. We would still get innovative medicines even if we weren't paying out the nose for them.

The authors even acknowledge this on page 4, "The cost-conscious environment also altered market structure. The number of new entrants decreased by 40%, driven by a 72% decline in U.S. manufacturers’ entry, with NO SIGNIFICANT CHANGE among foreign manufacturers, perhaps reflecting their relative cost advantage."

Why do foreign manufacturers have a cost advantage? Because they are used to justifying the cost of their devices to national Health Technology Assessment agencies. Other countries have medical device companies that can innovate without a massive subsidy from the US taxpayer.

This is like your explainer on how important it is to make an industry that can compete internationally rather than relying on local government subsidies and captive market.

2) Let them eat R&D dollars!

Their "Our calculations suggest the value of lost innovation may fully offset the direct cost savings from the price cuts." is very misleadingly worded and framed. They are very strongly implying that the the "value of lost innovation, measured by reduced R&D expenditures, amounting to $2.9 billion annually following the price reform" (page 27) is comparable to "Medicare saved$ 3.8 billion annually in DME spending, adjusting for inflation." (page 28).

The "Value of lost innovation" is company spending on R&D. If Merck spends 10 million$ less on R&D in 2024 than it did in 2023, some people might lose their jobs and the medical research sector would shrink. There may be some long term effects on new drugs/devices but this is ultimately a kind of industrial R&D spending.

Conversely, if Medicare has 10 million$ more to spend, that's medical procedures, that's medicines, that is patient care, that is lives saved directly and immediately.

The authors word their comparison to make it seem like a dollar of lost R&D is doing the same thing as a dollar of lost Medicare spending, but it really, really is not.

Expand full comment
85 more comments...

No posts